Founder and principal consultant David Knight, Ph.D. has more than 25 years of experience in the biotechnology industry. He has played key roles in the discovery and development of highly successful marketed biopharmaceuticals and biotherapeutics including ReoPro™, Remicade™, Simponi™ and Stelara™.
Knight BioAdvisors provides strategic support to the biopharmacutical industry, specializing in monoclonal antibody-related programs from discovery to IND.
Ready to get in touch? Start working with Knight BioAdvisors and move your biopharmaceutical products forward today.
Therapeutic Monoclonal Antibodies More than 80 issued US patents